Community Bank & Trust Waco Texas Has $626,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Community Bank & Trust Waco Texas cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,801 shares of the medical equipment provider’s stock after selling 350 shares during the quarter. Community Bank & Trust Waco Texas’ holdings in Zimmer Biomet were worth $626,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Missouri Trust & Investment Co raised its holdings in Zimmer Biomet by 2.6% during the third quarter. Missouri Trust & Investment Co now owns 12,035 shares of the medical equipment provider’s stock worth $1,299,000 after acquiring an additional 303 shares in the last quarter. Versor Investments LP increased its holdings in shares of Zimmer Biomet by 93.4% in the third quarter. Versor Investments LP now owns 18,565 shares of the medical equipment provider’s stock valued at $2,004,000 after purchasing an additional 8,965 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter valued at about $28,000. River Global Investors LLP lifted its position in Zimmer Biomet by 31.3% during the third quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock worth $2,276,000 after acquiring an additional 5,030 shares during the last quarter. Finally, Covestor Ltd boosted its stake in Zimmer Biomet by 36.3% in the 3rd quarter. Covestor Ltd now owns 1,088 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 290 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $109.95 on Wednesday. The company has a market capitalization of $21.89 billion, a PE ratio of 20.90, a P/E/G ratio of 2.01 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a 50-day moving average price of $106.26 and a two-hundred day moving average price of $110.25. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.65 earnings per share. Analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Analysts Set New Price Targets

ZBH has been the topic of several research reports. JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday, September 16th. Truist Financial raised their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company boosted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Robert W. Baird decreased their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, Wolfe Research initiated coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $124.11.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.